HHM Wealth Advisors LLC acquired a new position in shares of Amgen, Inc. (NASDAQ:AMGN) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund acquired 812 shares of the medical research company’s stock, valued at approximately $165,000.

Other large investors also recently added to or reduced their stakes in the company. Salomon & Ludwin LLC grew its position in Amgen by 125.0% during the 4th quarter. Salomon & Ludwin LLC now owns 108 shares of the medical research company’s stock worth $26,000 after purchasing an additional 60 shares during the last quarter. CLS Investments LLC grew its position in Amgen by 175.4% during the 4th quarter. CLS Investments LLC now owns 157 shares of the medical research company’s stock worth $38,000 after purchasing an additional 100 shares during the last quarter. Altshuler Shaham Ltd grew its position in Amgen by 273.9% during the 4th quarter. Altshuler Shaham Ltd now owns 172 shares of the medical research company’s stock worth $42,000 after purchasing an additional 126 shares during the last quarter. Column Capital Advisors LLC grew its position in Amgen by 98.0% during the 1st quarter. Column Capital Advisors LLC now owns 194 shares of the medical research company’s stock worth $39,000 after purchasing an additional 96 shares during the last quarter. Finally, Moser Wealth Advisors LLC purchased a new stake in Amgen during the 4th quarter worth approximately $48,000. 75.57% of the stock is currently owned by institutional investors.

NASDAQ:AMGN traded up $0.24 during mid-day trading on Friday, hitting $224.37. The stock had a trading volume of 1,378,125 shares, compared to its average volume of 2,754,168. The stock has a 50-day simple moving average of $230.73 and a two-hundred day simple moving average of $225.39. The company has a market capitalization of $132.24 billion, a PE ratio of 17.51, a PEG ratio of 1.92 and a beta of 0.97. Amgen, Inc. has a twelve month low of $166.68 and a twelve month high of $244.99. The company has a current ratio of 1.59, a quick ratio of 1.28 and a debt-to-equity ratio of 3.16.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $4.17 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.70 by $0.47. The firm had revenue of $6.16 billion for the quarter, compared to analysts’ expectations of $6.01 billion. Amgen had a net margin of 32.03% and a return on equity of 90.75%. The firm’s revenue was up 10.9% compared to the same quarter last year. During the same quarter last year, the company earned $3.56 earnings per share. Sell-side analysts predict that Amgen, Inc. will post 15.58 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, June 8th. Investors of record on Monday, May 18th will be issued a $1.60 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.40 annualized dividend and a yield of 2.85%. Amgen’s dividend payout ratio (DPR) is 43.18%.

In related news, Director R Sanders Williams sold 425 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $237.31, for a total value of $100,856.75. Following the sale, the director now owns 5,834 shares of the company’s stock, valued at $1,384,466.54. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Ronald D. Sugar sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $233.35, for a total transaction of $233,350.00. Following the completion of the sale, the director now directly owns 15,636 shares in the company, valued at approximately $3,648,660.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,425 shares of company stock worth $563,477. 0.25% of the stock is owned by corporate insiders.

Several analysts have weighed in on AMGN shares. Oppenheimer started coverage on shares of Amgen in a research report on Friday, May 1st. They set a “buy” rating and a $252.00 target price on the stock. Morgan Stanley boosted their target price on shares of Amgen from $267.00 to $280.00 and gave the stock an “overweight” rating in a research report on Friday, May 1st. SVB Leerink boosted their target price on shares of Amgen from $219.00 to $249.00 and gave the stock a “market perform” rating in a research report on Friday, May 1st. Bank of America upped their price objective on shares of Amgen from $250.00 to $265.00 and gave the company a “buy” rating in a report on Friday, May 1st. Finally, Cowen reaffirmed a “buy” rating on shares of Amgen in a report on Friday, January 31st. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seventeen have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $244.65.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Recommended Story: Google Finance Portfolio Tips and Tricks

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.